Hormone OptimizationResearch

GHRP-2 Therapy: Complete Guide

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic growth hormone secretagogue that stimulates the pituitary gland via the ghrelin receptor. It is considered more potent than GHRP-6 for GH release but with a somewhat less pronounced appetite-stimulating effect. Like other GHRPs, it is often used in combination with GHRH analogs.

Typical cost: $80 - $250/month

Written by

Megan Williams

Editor-in-Chief

Reviewed by

Brian Williams

Co-founder & Research Editor

Last updated

May 26, 2026

What is GHRP-2?

What Is GHRP-2?

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin/GHS receptor (GHS-R1a) to stimulate pituitary growth hormone release. It is considered the most potent of the GHRP family of peptides, producing the greatest GH release per dose compared to GHRP-6 and ipamorelin.

GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) was developed as a second-generation growth hormone secretagogue with improved potency and a more favorable side effect profile compared to GHRP-6. It is sometimes referred to by its research designation KP-102.

Position Among GH Secretagogues

GHRP-2 occupies a middle ground between GHRP-6 and ipamorelin:

Most potent GH release of the GHRP peptides
Moderate appetite stimulation (more than ipamorelin, less than GHRP-6)
Some cortisol and prolactin effects (more than ipamorelin, similar to GHRP-6)
Excellent synergy with GHRH analogs

Clinical Applications

Maximum GH stimulation: When the highest GH release is desired
GH deficiency assessment: Used as a diagnostic tool for GH reserve testing
Body composition optimization: Supporting lean mass and fat reduction through robust GH/IGF-1 axis stimulation
Anti-aging protocols: For patients wanting stronger GH stimulation than ipamorelin provides
Recovery enhancement: Post-exercise and injury recovery through potent GH-mediated repair

GHRP-2 is available through compounding pharmacies and is used in Japan as an approved diagnostic agent for GH deficiency testing, providing some level of regulatory validation for its pharmacology and safety.

How GHRP-2 Works

GHS-R1a Receptor Agonism

GHRP-2 is a potent agonist of the GHS-R1a receptor (ghrelin receptor), the same G-protein coupled receptor targeted by endogenous ghrelin and other GHRP family members. GHRP-2's structural modifications give it the highest binding affinity and intrinsic activity of the GHRP family.

Enhanced GH Release Potency

Compared to GHRP-6, GHRP-2 produces:

Greater peak GH levels at equivalent doses
Larger area-under-the-curve (AUC) for GH release over time
More consistent GH response across individuals

Somatostatin Modulation

Like GHRP-6, GHRP-2 partially suppresses somatostatin release from the hypothalamus. This dual action (direct pituitary stimulation + somatostatin suppression) contributes to its high GH-releasing potency and explains the synergy observed when combined with GHRH analogs.

Appetite and Hormonal Effects

GHRP-2 activates hypothalamic GHS-R1a receptors, producing moderate appetite stimulation — stronger than ipamorelin but weaker than GHRP-6. It also causes:

Mild cortisol elevation: Through ACTH stimulation, similar to GHRP-6
Mild prolactin increase: Transient elevation at higher doses
No significant effect on aldosterone or thyroid hormones

GHRH Synergy

The combination of GHRP-2 with GHRH analogs produces GH release that is synergistic rather than simply additive. GHRP-2's somatostatin suppression removes the "brake" on GH release, while GHRH simultaneously "accelerates" GH secretion, producing combined effects that can be 5–10x greater than either alone.

Benefits & Uses

Benefits of GHRP-2

Strongest GH release among GHRPs: GHRP-2 is the most potent growth hormone-releasing peptide, producing peak GH levels exceeding those of GHRP-6 and ipamorelin at equivalent doses. Studies show 5–8-fold increases in GH levels within 30 minutes.
Reliable and reproducible: GHRP-2 produces consistent GH release across a wide range of ages and body types, with less inter-individual variability than some other GH secretagogues.
Diagnostic utility: Approved in Japan as a diagnostic tool for GH deficiency testing, validating its reliable and potent GH-stimulating properties. This approval provides pharmacological validation beyond what most research peptides have.
Body composition improvement: Through robust GH/IGF-1 axis stimulation, GHRP-2 supports lean muscle gain and fat reduction more strongly than less potent secretagogues.
Moderate appetite stimulation: The appetite increase is moderate — enough to support caloric intake for muscle building without the extreme hunger seen with GHRP-6.
Enhanced recovery: Potent GH release translates to improved tissue repair, protein synthesis, and recovery from exercise and injury.
Sleep improvement: Like other GH secretagogues, pre-bedtime GHRP-2 enhances deep sleep quality through amplification of the nocturnal GH surge.
Neuroprotective potential: Research suggests ghrelin receptor agonism may have neuroprotective effects, including protection against neuronal damage and support for cognitive function.

Clinical Evidence & Research

Clinical and Research Evidence

GH release potency (Bowers et al., Journal of Clinical Endocrinology & Metabolism): Head-to-head comparison studies established GHRP-2 as the most potent GHRP family member, with greater peak GH release and AUC compared to GHRP-6 at equivalent doses.

Diagnostic use in Japan: GHRP-2 (as KP-102) is approved in Japan for the diagnosis of growth hormone deficiency. This regulatory approval validates its pharmacological properties and safety profile in a clinical diagnostic context.

GHRH synergy studies: Multiple studies demonstrated that the combination of GHRP-2 with GHRH produced synergistic GH release, with combined responses 5–10 times greater than either compound alone. This synergy forms the scientific basis for combination GH secretagogue protocols (Arvat et al., Journal of Clinical Endocrinology & Metabolism, 1997).

Age-related GH decline: Studies have shown that GHRP-2 can restore GH secretion in elderly subjects to levels comparable to younger adults, suggesting that the age-related decline in GH is primarily due to insufficient stimulation rather than pituitary failure (Broglio et al., European Journal of Endocrinology, 2002).

Appetite and energy regulation: Research on GHRP-2 and ghrelin receptor agonism has contributed to understanding of appetite regulation, energy homeostasis, and the gut-brain axis, with implications for treating eating disorders and cachexia.

"GHRP-2 is the most potent and effective of the synthetic growth hormone-releasing peptides, providing a reliable tool for both clinical research and therapeutic GH stimulation." — Bowers, Journal of Neuroendocrinology, 2012

Side Effects & Safety

Side Effect Profile

GHRP-2 has a well-characterized side effect profile from research use and clinical application in Japan.

Common Side Effects (Mild)

Appetite increase — Moderate hunger stimulation, typically 30–60 minutes post-injection. Less intense than GHRP-6 but more notable than ipamorelin.
Injection site reactions — Mild pain, redness, or swelling.
Water retention — Mild fluid retention, especially in early weeks. Self-limiting in most cases.
Flushing — Brief warmth or skin flushing post-injection.

Less Common Side Effects (Moderate)

Cortisol elevation — Mild transient increase in cortisol, similar to GHRP-6. Generally resolves within 1–2 hours and is not considered clinically significant at standard doses.
Prolactin elevation — Modest increase in prolactin at higher doses. Usually transient and clinically insignificant.
Tingling/numbness — Paresthesias related to GH effects.
Headache — Occasionally reported; typically mild.

Monitoring Recommendations

IGF-1 levels: To ensure GH response is appropriate and not excessive
Cortisol: Periodic monitoring, particularly if symptoms of cortisol excess develop
Prolactin: Check if symptoms of elevated prolactin occur (rare at standard doses)
Fasting glucose: GH affects insulin sensitivity; monitor in metabolically at-risk patients

Dosing & Administration

Standard Dosing Protocols

GHRP-2 Alone

Dose: 100–300 mcg subcutaneously per injection
Frequency: 1–3 times daily
Timing: On an empty stomach; pre-bedtime (most important), upon waking, and/or post-exercise

GHRP-2 + GHRH Analog Combination

GHRP-2: 100–200 mcg per injection
CJC-1295 (no DAC) or sermorelin: 100–200 mcg per injection
Combined in the same syringe: 1–3 times daily

Administration: Subcutaneous injection in the abdominal area. Must be administered in a fasting state (at least 2 hours after eating, 30+ minutes before eating) for optimal GH response.

Saturation dose: Research suggests that the GH response plateaus at approximately 200–300 mcg (the "saturation dose"). Higher doses do not produce proportionally more GH release and may increase cortisol and prolactin effects.

Cycle duration: 8–16 weeks with periodic breaks, or 3–6 months with monitoring. Some practitioners allow continuous use with monitoring.

Find GHRP-2 Providers Near You

Search our directory for qualified providers offering GHRP-2 therapy. Filter by location, telehealth, and more.

Browse Providers

GHRP-2 FAQ

Yes, GHRP-2 produces greater peak GH release than GHRP-6 at equivalent doses. It is considered the most potent of the GHRP family peptides. However, "stronger" GH release does not always mean "better" for every patient, as the choice should be based on the full clinical picture including side effect tolerance.

While GHRP-2 produces stronger GH release, ipamorelin is significantly more selective - it does not increase cortisol, prolactin, or appetite. For many patients seeking GH optimization for anti-aging or general wellness, ipamorelin's clean profile is preferred. GHRP-2 is chosen when maximum GH stimulation is prioritized over selectivity.

No, GHRP-2 causes moderate appetite stimulation that is less intense than GHRP-6 but still noticeable. Most patients find the hunger manageable, especially if they time their injection before a planned meal. The appetite effect diminishes somewhat with continued use.

Yes, GHRP-2 is approved in Japan specifically as a diagnostic tool for GH deficiency testing. Its reliable and potent GH-stimulating effect makes it an effective provocative agent for assessing pituitary GH reserve. This diagnostic application validates its pharmacological properties.

Research indicates the GH response to GHRP-2 plateaus at approximately 200-300 mcg per injection (the "saturation dose"). Increasing beyond this dose does not proportionally increase GH release but may increase cortisol and prolactin side effects. Most practitioners recommend staying at or below 300 mcg per injection.

Yes, combining GHRP-2 with CJC-1295 (without DAC) is a highly effective protocol. The two peptides work through different receptor systems (ghrelin receptor and GHRH receptor) and produce synergistic GH release that can be 5-10 times greater than either alone. They can be mixed in the same syringe for convenience.